Bioxyne Statistics

Total Valuation

Bioxyne has a market cap or net worth of AUD 86.59 million. The enterprise value is 85.32 million.

Market Cap	86.59M
Enterprise Value	85.32M

Important Dates

The next estimated earnings date is Friday, August 29, 2025.

Earnings Date	Aug 29, 2025
Ex-Dividend Date	n/a

Share Statistics

Bioxyne has 2.16 billion shares outstanding. The number of shares has increased by 6.63% in one year.

Current Share Class	2.16B
Shares Outstanding	2.16B
Shares Change (YoY)	+6.63%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	51.70%
Owned by Institutions (%)	n/a
Float	513.25M

Valuation Ratios

The trailing PE ratio is 30.98.

PE Ratio	30.98
Forward PE	n/a
PS Ratio	5.00
PB Ratio	12.61
P/TBV Ratio	12.03
P/FCF Ratio	609.01
P/OCF Ratio	53.83
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 24.02, with an EV/FCF ratio of 600.05.

EV / Earnings	38.14
EV / Sales	4.92
EV / EBITDA	24.02
EV / EBIT	28.96
EV / FCF	600.05

Financial Position

The company has a current ratio of 1.73, with a Debt / Equity ratio of 0.25.

Current Ratio	1.73
Quick Ratio	0.81
Debt / Equity	0.25
Debt / EBITDA	0.49
Debt / FCF	12.19
Interest Coverage	53.28

Financial Efficiency

Return on equity (ROE) is 51.99% and return on invested capital (ROIC) is 32.66%.

Return on Equity (ROE)	51.99%
Return on Assets (ROA)	18.73%
Return on Invested Capital (ROIC)	32.66%
Return on Capital Employed (ROCE)	36.08%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	1.76
Inventory Turnover	3.53

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +700.00% in the last 52 weeks. The beta is 0.24, so Bioxyne's price volatility has been lower than the market average.

Beta (5Y)	0.24
52-Week Price Change	+700.00%
50-Day Moving Average	0.03
200-Day Moving Average	0.02
Relative Strength Index (RSI)	68.85
Average Volume (20 Days)	6,491,236

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Bioxyne had revenue of AUD 17.33 million and earned 2.24 million in profits. Earnings per share was 0.00.

Revenue	17.33M
Gross Profit	8.09M
Operating Income	2.95M
Pretax Income	2.48M
Net Income	2.24M
EBITDA	3.37M
EBIT	2.95M
Earnings Per Share (EPS)	0.00

Full Income Statement

Balance Sheet

The company has 2.68 million in cash and 1.73 million in debt, giving a net cash position of 945,453 or 0.00 per share.

Cash & Cash Equivalents	2.68M
Total Debt	1.73M
Net Cash	945,453
Net Cash Per Share	0.00
Equity (Book Value)	6.87M
Book Value Per Share	0.00
Working Capital	4.91M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.61 million and capital expenditures -1.47 million, giving a free cash flow of 142,187.

Operating Cash Flow	1.61M
Capital Expenditures	-1.47M
Free Cash Flow	142,187
FCF Per Share	0.00

Full Cash Flow Statement

Margins

Gross margin is 46.66%, with operating and profit margins of 17.00% and 12.91%.

Gross Margin	46.66%
Operating Margin	17.00%
Pretax Margin	14.32%
Profit Margin	12.91%
EBITDA Margin	19.44%
EBIT Margin	17.00%
FCF Margin	0.82%

Dividends & Yields

Bioxyne does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-6.63%
Shareholder Yield	n/a
Earnings Yield	2.58%
FCF Yield	0.16%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Bioxyne has an Altman Z-Score of 2.67 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.67
Piotroski F-Score	5